‘Business of science’ digest - October 2020

In the first of a new monthly digest, we highlight recent ‘business of science’ articles from Springer Nature research journals, magazines and supplements. This digest looks at the latest drugs approved by the US FDA and a $1bn antibody development deal, peeps into the Chan Zuckerberg Biohub, and offers advice to budding science entrepreneurs.
Raveena obtained her bachelor's degree in biochemistry from the University of Leeds, UK. She has worked in the biopharma industry for more than 15 years, focusing on dealmaking, partnering and licensing throughout. In her first role, Raveena started as an editorial assistant, moving on to become content editor, specifically involved with conducting partner searches to identify both products/technologies and partners for pharmaceutical clients. She then worked for a biopharma reports publisher, editing and writing dealmaking-focused reports. In 2015 Raveena became the editor of Biopharma Dealmakers.

Search for this author in:

Four steps to science spin-off success

Want to get ahead in business? You’ll need resilience and persistence, says Barbara Domayne-Hayman, entrepreneur-in-residence at the Francis Crick Institute in London. “You get kicked in the teeth and rejected time and time again. I prefer to talk about ‘knockbacks’ rather than ‘failure’, which sounds too terminal. Allow yourself 20 minutes to wallow and then pick yourself up and think of new ways forward.”


What you need to know when working with big pharma

Ask any pharma executive whether their company is interested in academic collaborations and the answer is a resounding “yes.” So why do so few academic institutions have success stories to share?

Nature Biotechnology

Inside the Chan Zuckerberg Biohub

The Chan Zuckerberg Biohub is both an institute and an academic network devoted to accelerating research via cutting edge technologies and open science. Its focus on single-cell analysis and infectious disease has placed it front and center in the pandemic.

Nature Biotechnology

Evolution of the COVID-19 vaccine development landscape

The COVID-19 vaccine R&D landscape has developed at unprecedented scale and speed since an initial analysis by Nature Reviews Drug Discovery in April identified 115 candidates in the pipeline (Nat. Rev. Drug Discov. 19, 305–306; 2020). In this updated overview, NRDD focuses on candidates in clinical trials and provides initial perspectives on their clinical development.

Nature Reviews Drug Discovery

How to distribute a COVID-19 vaccine ethically

As vaccine developers race toward safe and effective candidates to stem the tide of the pandemic, health officials and policy makers are grappling with a significant philosophical and ethical challenge: how to best allocate limited vaccines doses to the world’s population.

Scientific American

FDA new drug approvals in Q2 2020

With 11 new drugs approved, fears of major disruption to approval timelines were not realized, and at the halfway point of 2020, the US regulator has now approved almost double the 13 drugs approved in the first half of 2019. However, data submission for many of these drugs would have occurred before March, and so the full impact of COVID-19 on drug approvals might not be felt until later in the year.

Nature Reviews Drug Discovery

Pharmaceutical firms commit US$1 billion to antibiotic development

Twenty-four large and medium-sized pharmaceutical firms are backing a US$1 billion fund to steward antibiotics through phase II and III trials. Can they also break an antibiotic reimbursement impasse?

Nature Reviews Drug Discovery

Spinoff Prize: last chance to enter

The deadline to apply for Nature Research’s Spinoff Prize, established in partnership with Merck, is fast approaching. The prize, now in its second year, showcases and celebrates global excellence in the commercialisation of research. Applications need to be in by November 15 2020. Find out more here.


Nature Briefing

An essential round-up of science news, opinion and analysis, delivered to your inbox every weekday.